← All trials
NCT01297959
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2012
- Primary completion
- Oct 1, 2015
- Completion date
- Jun 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 1350
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Excited States, LLCLead sponsor
- University of California, IrvineOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- Excited States, LLCStudy director
- Oregon Health and Science UniversityStudy chair
- Veristat, Inc.Collaborator
- Biotec Services International LtdCollaborator
- CBR International Corp.Collaborator
- EurofinsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.